JIM JOYCECHAIRMAN, CEO

REDCHIP EQUITIES CONFERENCENASDAQ MARKETPLACE

July 21, 2010

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER® AND OTHER PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.

Forward looking statements

IF YOU HAVE CANCER…………

CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER

CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER

THE FIRST MEDICAL DEVICE TO SELECTIVELY FILTER VIRUSES AND IMMUNOSUPPRESSIVE PARTICLES FROM CIRCULATION

THE HEMOPURIFIER®

Leveraging Established Infrastructure

Selectively Targets the Removal of:

The Most Advanced Broad-Spectrum Countermeasure

Bioterror & Pandemic Threats

Virus CollaboratorsHuman Variety

Ebola CDC / USAMRIID YES

Dengue NIV / WHO YES

Lassa SFBR YES

West Nile Battelle YES

H5N1 Avian Battelle YES

Spanish Flu of 1918-R Battelle YES

2009 H1N1 Swine Battelle YES

Monkey pox Battelle NO

OUR HEMOPURIFIER® IS THEONLY TREATMENT STRATEGY TO ADDRESS DRUG RESISTANT AIDS PATIENTS

Human Immunodeficiency Virus (HIV)

DO HIV INFECTED INDIVIDUALS HAVE TO DIE WHEN THEY NO LONGER RESPOND TO THEIR MEDS?

IN THE ABSENCE OF DRUG THERAPY

HIV/AIDS Patient Data

92% reduction of viral load Improved CD4+ T-cell %

30 DAY STUDY – THREE HEMOPURIFIER® TREATMENTS PER WEEK

AIDS

TO ACCELERATE EARLY VIRAL LOAD REDUCTION OF HCV STANDARD OF CARE (SOC) DRUG THERAPY

Hepatitis-C Virus (HCV)

CAN SELECTIVE VIRAL FILTRATION IMPROVE HCV CURE RATES?

IN THE ABSENCE OF DRUG THERAPY

5 Day HCV Treatment Studies

ONE WEEK STUDY – THREE HEMOPURIFIER® TREATMENTS

Validation for Viral Filtration Therapy

Success %

HEMOPURIFIER®+ TELAPRIVIR+ INTERFERON-RIBAVIRIN (SOC)= ____% SVR?

An Enduring Adjunct Opportunity

Hemopurifier® + Current SOC Hemopurifier® + Future Iterations

of SOC 65 drugs in competition

IF YOU HAVE CANCER…………

EXOSOMES ARE SECRETED BY ALL TUMORS, LYMPHOMAS, & LEUKEMIAS

Exosomes are Immunosuppressive

Induce Apoptosis Disrupt T-Cell Signaling Inhibit Cytokine Production Angiogenesis Metastasis

Tumor-Secreted Exosomes

WE ARE AT THE FOREFRONT OF THE EMERGING CANCER EXOSOME FIELD

Full-Spectrum Cancer Opportunity

ARE EXOSOMES PRESENT?

Diagnosis of Cancer

WHAT QUANTITY OF EXOSOMES ARE PRESENT IN BLOOD?

Monitoring Cancer Progression

Enzyme Linked Lectin Specific Assay

ELLSA

REMOVE THE PRESENCE OF IMMUNOSUPPRESSIVE EXOSOMES

Cancer Therapy

OUR HEMOPURIFIER® IS THE SOLE THERAPEUTIC STRATEGY TO ADDRESS IMMUNSUPPRESSIVE EXOSOMES

MAXIMIZING THE ABILITY OF THE IMMUNE SYSTEM TO COMBAT CANCER?

A Complementary Therapeutic

Targets Benefit w/o Stacking additional drug

toxicity Adding drug interaction risk

DOES THE MEDICAL COMMUNITY HAVE INTEREST IN EXOSOMES?

Interest in Exosomes

DOES THE MEDICAL COMMUNITY HAVE INTEREST IN AETHLON MEDICAL?

>600

Push vs. Pull

ADVANCING COLLABORATIVE RELATIONSHIPS WITH THOUGHT LEADERS REPRESENTING PREMIER CANCER TREATMENT INSTITUTES

A Foundation to Build Value

www.npr.org/templates/story/story.php?storyId=128339775

Guidance DisclosureRemainder of 2010

Remainder of 2010 Guidance

Infectious Disease Initiate Medanta-Medicity HCV

adjunct treatment studies (establish revenue stream)

Increase treatment site opportunities Define clinical plans beyond India

Cancer Data from multiple studies

Hemopurifier® & ELLSA Disclosure of collaborative partners Define U.S. clinical programs

CREATING REVOLUTIONARY DEVICESTHAT ADDRESS INFECTIOUS DISEASE& CANCER

CHANGE THE WAY PEOPLE THINK ABOUT TREATING INFECTIOUS DISEASE & CANCER

AEMD

JIM JOYCECHAIRMAN, CEO

8910 UNIVERSITY CENTER LANESAN DIEGO, CA. 92122

JJ@AETHLONMEDICAL.COM858.459.7800 X301

ASSISTANT: CHARLENE OWENCOWEN@AETHLONMEDICAL.COM858.459.7800 X305